When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off ...

Pathos AI has launched a $400 million funding round and already raised nearly $283 million. The Chicago-based startup formed ...

Amid a bullish backdrop for the broader market, Tempus AI (NASDAQ: TEM) stock is posting big gains Wednesday. The company's ...

BTIG analyst Mark Massaro has initiated coverage on Tempus AI (TEM), with a Buy rating and a price target of $60, implying 48 ...

Tempus AI announced a collaboration with AstraZeneca and Pathos AI. The deal will generate $200 million for Tempus AI in data ...

Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with ...

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.

Tempus AI is a leader in applying AI solutions to cancer diagnosis. The company announced a new platform for speeding up the discovery of new drug targets. Since it's still unprofitable ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this.